{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:32:13Z","timestamp":1782934333962,"version":"3.54.5"},"reference-count":109,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T00:00:00Z","timestamp":1699747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that is often associated with relapse and drug resistance after standard chemotherapy or targeted therapy, particularly in older patients. Hematopoietic stem cell transplants are looked upon as the ultimate salvage option with curative intent. Adoptive cell therapy using chimeric antigen receptors (CAR) has shown promise in B cell malignancies and is now being investigated in AML. Initial clinical trials have been disappointing in AML, and we review current strategies to improve efficacy for CAR approaches. The extensive number of clinical trials targeting different antigens likely reflects the genetic heterogeneity of AML. The limited number of patients reported in multiple early clinical studies makes it difficult to draw conclusions about CAR safety, but it does suggest that the efficacy of this approach in AML lags behind the success observed in B cell malignancies. There is a clear need not only to improve CAR design but also to identify targets in AML that show limited expression in normal myeloid lineage cells.<\/jats:p>","DOI":"10.3390\/hematolrep15040063","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T08:44:27Z","timestamp":1699865067000},"page":"608-626","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations"],"prefix":"10.3390","volume":"15","author":[{"given":"Swati","family":"Garg","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-827X","authenticated-orcid":false,"given":"Wei","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Griffin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-4199","authenticated-orcid":false,"given":"Martin","family":"Sattler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e04177","DOI":"10.7554\/eLife.04177","article-title":"Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses","volume":"3","author":"Chiba","year":"2014","journal-title":"eLife"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The Intriguing History of Cancer Immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fimmu.2016.00365","article-title":"Cancers Related to Immunodeficiencies: Update and Perspectives","volume":"7","author":"Mortaz","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: A brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T Cell Immunotherapy for Cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: Current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100578","DOI":"10.1016\/j.blre.2019.05.002","article-title":"Cellular therapy for acute myeloid Leukemia\u2013Current status and future prospects","volume":"37","author":"Hansrivijit","year":"2019","journal-title":"Blood Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41581-022-00633-5","article-title":"Trained immunity\u2014basic concepts and contributions to immunopathology","volume":"19","author":"Ochando","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41568-023-00562-w","article-title":"Innate lymphoid cells and innate-like T cells in cancer\u2014at the crossroads of innate and adaptive immunity","volume":"23","author":"Ruf","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","article-title":"Harnessing innate immunity in cancer therapy","volume":"574","author":"Cornen","year":"2019","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T Cell Activation","volume":"27","author":"Koretzky","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0021-9258(17)49904-2","article-title":"The structural basis of T-cell receptor (TCR) activation: An enduring enigma","volume":"295","author":"Mariuzza","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.it.2012.05.006","article-title":"MHC restriction is imposed on a diverse T cell receptor repertoire by CD4 and CD8 co-receptors during thymic selection","volume":"33","author":"Tikhonova","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41577-018-0007-5","article-title":"Understanding the drivers of MHC restriction of T cell receptors","volume":"18","author":"Gras","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-017-01661-7","article-title":"Conventional CD4+ T cells present bacterial antigens to induce cytotoxic and memory CD8+ T cell responses","volume":"8","author":"Zorita","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature24627","article-title":"Structure of the human MHC-I peptide-loading complex","volume":"551","author":"Blees","year":"2017","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3389\/fimmu.2017.01467","article-title":"Membrane Rafts in T Cell Activation: A Spotlight on CD28 Costimulation","volume":"8","author":"Zumerle","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2004-04-1596","article-title":"The CD28 family: A T-cell rheostat for therapeutic control of T-cell activation","volume":"105","author":"Riley","year":"2005","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune Escape Mechanisms as a Guide for Cancer Immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"785091","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"868695","DOI":"10.3389\/fphar.2022.868695","article-title":"The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","article-title":"Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B","volume":"23","author":"Musella","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41423-022-00953-3","article-title":"Cancer cells escape the immune system by increasing stemness through epigenetic reprogramming","volume":"20","author":"Costoya","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2478\/ahp-2020-0002","article-title":"A brief history of CAR-T cells: From laboratory to the bedside","volume":"51","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri1265","article-title":"Monoclonal antibodies: The story of a discovery that revolutionized science and medicine","volume":"4","author":"Alkan","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"eabl3995","DOI":"10.1126\/sciimmunol.abl3995","article-title":"Size-dependent activation of CAR-T cells","volume":"7","author":"Xiao","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Fujiwara, K., Tsunei, A., Kusabuka, H., Ogaki, E., Tachibana, M., and Okada, N. (2020). Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells, 9.","DOI":"10.3390\/cells9051182"},{"key":"ref_39","first-page":"748","article-title":"Allogeneic CAR T cells show promise","volume":"19","author":"Sidaway","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e005701","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"640082","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma","volume":"12","author":"Bedoya","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","article-title":"Polymer- and lipid-based gene delivery technology for CAR T cell therapy","volume":"353","author":"Pinto","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hofmann, S., Schubert, M.-L., Wang, L., He, B., Neuber, B., Dreger, P., M\u00fcller-Tidow, C., and Schmitt, M. (2019). Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). J. Clin. Med., 8.","DOI":"10.3390\/jcm8020200"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13402-021-00593-1","article-title":"CAR T cell therapy as a promising approach in cancer immunotherapy: Challenges and opportunities","volume":"44","author":"Akhoundi","year":"2021","journal-title":"Cell. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/ijc.31147","article-title":"Chimeric antigen receptor transduced T cells: Tuning up for the next generation","volume":"142","author":"Schubert","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10313","DOI":"10.1182\/blood-2022-169142","article-title":"Phase 1\/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","volume":"104","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chen, Y.-J., Abila, B., and Kamel, Y.M. (2023). CAR-T: What Is Next?. Cancers, 15.","DOI":"10.3390\/cancers15030663"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Andrea, A.E., Chiron, A., Bessoles, S., and Hacein-Bey-Abina, S. (2020). Engineering Next-Generation CAR-T Cells for Better Toxicity Management. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228620"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12943-022-01669-8","article-title":"Tumor buster\u2014Where will the CAR-T cell therapy \u2018missile\u2019 go?","volume":"21","author":"Qu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","article-title":"A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e142030","DOI":"10.1172\/JCI142030","article-title":"Insight into next-generation CAR therapeutics: Designing CAR T cells to improve clinical outcomes","volume":"131","author":"Roselli","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1034707","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells-new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gumber, D., and Wang, L.D. (2022). Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine, 77.","DOI":"10.1016\/j.ebiom.2022.103941"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2022016937","article-title":"How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL","volume":"141","author":"Myers","year":"2023","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1085978","DOI":"10.3389\/fimmu.2022.1085978","article-title":"Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia","volume":"13","author":"Schorr","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s13287-021-02420-8","article-title":"Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MOH.0000000000000703","article-title":"Chimeric antigen receptor T-cell therapy in acute myeloid leukemia","volume":"29","author":"Koedam","year":"2022","journal-title":"Curr. Opin. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Vishwasrao, P., Li, G., Boucher, J.C., Smith, D.L., and Hui, S.K. (2022). Emerging CAR T Cell Strategies for the Treatment of AML. Cancers, 14.","DOI":"10.3390\/cancers14051241"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-Based Map of the Human Proteome","volume":"347","author":"Fagerberg","year":"2015","journal-title":"Science"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41588-019-0351-9","article-title":"Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration","volume":"51","author":"Ratnapriya","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12859-018-2486-6","article-title":"iDEP: An integrated web application for differential expression and pathway analysis of RNA-Seq data","volume":"19","author":"Ge","year":"2018","journal-title":"BMC Bioinform."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/ng.3646","article-title":"Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution","volume":"48","author":"Corces","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Liu, J., Tong, J., and Yang, H. (2022). Targeting CD33 for acute myeloid leukemia therapy. BMC Cancer, 22.","DOI":"10.1186\/s12885-021-09116-5"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Molica, M., Perrone, S., Mazzone, C., Niscola, P., Cesini, L., Abruzzese, E., and de Fabritiis, P. (2021). CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers, 13.","DOI":"10.3390\/cancers13133214"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell\u2013engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wang, J., Wang, W., Chen, H., Li, W., Huang, T., Zhang, W., Ling, W., Lai, P., Wang, Y., and Geng, S. (2021). C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/6643948"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","article-title":"CLT030, a leukemic stem cell\u2013targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia","volume":"2","author":"Jiang","year":"2018","journal-title":"Blood Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","article-title":"An Anti\u2013CLL-1 Antibody\u2013Drug Conjugate for the Treatment of Acute Myeloid Leukemia","volume":"25","author":"Zheng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: Still challenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.3324\/haematol.2017.186742","article-title":"NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed\/refractory acute myeloid leukemia patient","volume":"103","author":"Sallman","year":"2018","journal-title":"Haematologica"},{"key":"ref_83","first-page":"254","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wu, Z., Zhang, H., Wu, M., Peng, G., He, Y., Wan, N., and Zeng, Y. (2021). Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia. Biomed. Pharmacother., 137.","DOI":"10.1016\/j.biopha.2021.111299"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12964-023-01118-z","article-title":"KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: A novel therapeutic target identified by enChIP","volume":"21","author":"Alkhayer","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"22062","DOI":"10.1038\/s41598-021-01300-8","article-title":"Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis","volume":"11","author":"Farber","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1007783","DOI":"10.3389\/fonc.2022.1007783","article-title":"Targeting CD38 for acute leukemia","volume":"12","author":"Zhong","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: A novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Diorio","year":"2023","journal-title":"Blood Adv."},{"key":"ref_90","first-page":"e22309","article-title":"The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients","volume":"14","author":"Raza","year":"2022","journal-title":"Cureus"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2141.2011.08595.x","article-title":"Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms","volume":"153","author":"Ossenkoppele","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_92","first-page":"42","article-title":"Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia","volume":"9","author":"Ma","year":"2018","journal-title":"Leuk. Res. Rep."},{"key":"ref_93","first-page":"272","article-title":"CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia","volume":"27","author":"Atilla","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40164-022-00318-6","article-title":"CD7-directed CAR T-cell therapy: A potential immunotherapy strategy for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Cao","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1170968","DOI":"10.3389\/fimmu.2023.1170968","article-title":"Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: Recent advances","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7831","DOI":"10.1002\/cam4.4284","article-title":"Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical Evaluation of B7-H3\u2013specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1182\/blood.2021014671","article-title":"Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML","volume":"139","author":"Tyagi","year":"2022","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1152457","DOI":"10.3389\/fimmu.2023.1152457","article-title":"Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis","volume":"14","author":"Shahzad","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): Haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2352-3026(23)00002-9","article-title":"Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome","volume":"10","author":"Chua","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1182\/blood-2022-166790","article-title":"Preclinical Development of a CAR-T Cell Approach Targeting the CD84 Antigen Associated to Pediatric Acute Myeloid Leukemia","volume":"140","author":"Pigazzi","year":"2022","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.1182\/blood-2022-165339","article-title":"CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia","volume":"140","author":"Casals","year":"2022","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2022008304","article-title":"Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia","volume":"7","author":"Kirkey","year":"2023","journal-title":"Blood Adv."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Shao, R., Li, Z., Xin, H., Jiang, S., Zhu, Y., Liu, J., Huang, R., Xu, K., and Shi, X. (2023). Biomarkers as targets for CAR-T\/NK cell therapy in AML. Biomark. Res., 11.","DOI":"10.1186\/s40364-023-00501-9"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-141515","article-title":"Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Atilla, E., and Benabdellah, K. (2023). The Black Hole: CAR T Cell Therapy in AML. Cancers, 15.","DOI":"10.20944\/preprints202304.0482.v1"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Xie, G., Dong, H., Liang, Y., Ham, J.D., Rizwan, R., and Chen, J. (2020). CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine, 59.","DOI":"10.1016\/j.ebiom.2020.102975"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/4\/63\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:21:55Z","timestamp":1760131315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/4\/63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,12]]},"references-count":109,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["hematolrep15040063"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep15040063","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,12]]}}}